Company news

MBX Biosciences, Inc. news in 2025

MBX Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

December 14, 2025

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

November 17, 2025

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 5, 2025

MBX Biosciences to Participate in November Investor Conferences

October 19, 2025

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

September 28, 2025

MBX Biosciences Announces Pricing of Upsized Public Offering

September 23, 2025

MBX Biosciences Announces Proposed Public Offering

September 21, 2025

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

September 21, 2025

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

September 18, 2025

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

September 3, 2025

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 6, 2025

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

June 22, 2025

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

June 15, 2025

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

June 9, 2025

MBX Biosciences to Participate in June Investor Conferences

May 19, 2025

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 11, 2025

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

April 21, 2025

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

April 6, 2025

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 25, 2025

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 16, 2025

MBX Biosciences Announces Additions to Leadership Team

March 4, 2025

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

March 2, 2025

MBX Biosciences to Participate in March Investor Conferences

February 17, 2025

MBX Biosciences to Participate in Upcoming February Investor Conferences

January 22, 2025

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

January 6, 2025

Calls in 2025

Decks in 2025